ReviewGut and liver2019
Recurrent
Review in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04259931 (PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA), which is not on this map. Cited by 136 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
Who cites it
136 citing papers in PubMed, 3 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Pooled it
- Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection.Frontiers in cellular and infection microbiology · 2022Pooled it
- Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.BMC infectious diseases · 2021Pooled it
- Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial.Nature communications · 2026Trial
- Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.Nature medicine · 2025Trial
- Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.Microbiome · 2020Trial
- Review
- Identification and Characterization of Patient Populations at High Risk for Clostridioides difficile Infection (CDI): A Narrative Review.Infectious diseases and therapy · 2026Review
- Lab-in-a-Tube System Integrating Hierarchically Wrinkled Electrodes and DNAzyme-Functionalized Beads for Diagnosis of Clostridioides difficile Infection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Impact of Hospital-Based Fidaxomicin Use Criteria onInfectious disease reports · 2026Article
- A programmed reset mechanism primesScience advances · 2026Article
- Carbadox, a veterinary growth promoter exhibits anticlostridial activity through induction of oxidative stress in Clostridioides difficile.Gut pathogens · 2026Article
- Clinical Outcomes of Metronidazole Monotherapy Versus Metronidazole PlusBiotech (Basel (Switzerland)) · 2026Article
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2026Article
- Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Observational
- Whole-genome characteristics of isolates from recurrentMicrobiology spectrum · 2026Article
- Bile acid dependent attenuation of toxin mediated disease is independent of colonization resistance againstbioRxiv : the preprint server for biology · 2026Article
- Article
76 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common cause of antibiotic-associated diarrhea is
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.